ArticleScientific reports2025
Genomic epidemiology and characterization of difficult-to-treat resistant Pseudomonas aeruginosa isolates co-harboring bla
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Detection of carbapenem resistance mechanisms in difficult-to-treat Pseudomonas aeruginosa clinical isolates from a tertiary care hospital in Egypt.BMC microbiology · 2026Article
- Evaluation of Short Versus Long Course of Tobramycin Combined with Piperacillin/Tazobactam Against Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial resistance patterns and carbapenemase gene distribution in pediatric Pseudomonas aeruginosa isolates: molecular and epidemiological insights from an Iranian referral center.BMC microbiology · 2026Article
- Parallel microevolution of multidrug resistance and hypermucoviscosity in two carbapenem-resistant Pseudomonas aeruginosa clinical isolates with strikingly divergent virulence outcomes.BMC microbiology · 2026Article
- Emergence of ST1076 as a dominant high-risk clone carryingFrontiers in microbiology · 2026Article
- Whole-genome sequencing reveals molecular characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Molecular insights into the persistence and co-occurrence of two different carbapenem-resistantMicrobiology spectrum · 2025Article
- Precise pathogen detection and clinical characterization of bronchiectasis.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA) is an MDR subset resistant to all first-line antipseudomonal agents. It is particularly concerning in respiratory infections like bronchiectasis, leading to poor outcomes, limited treatment options, and higher healthcare costs. This study aimed to investigate the antimicrobial resistance profiles and sequence types (STs) of Pseudomonas aeruginosa isolates, providing insight into their resistance patterns and the factors contributing to resistance. In 2021, 38 multidrug-resistant P. aeruginosa isolates were collected from bronchiectasis patients from a single medical center in Ningbo, China. The isolates were obtained from various clinical samples, including sputum, secretion, urine, and blood. Minimum inhibitory concentration testing revealed that 97.4% of the isolates were sensitive to amikacin and tobramycin, with none showing resistance to polymyxin B. Resistance rates to imipenem and meropenem were 84.2% and 57.9%, respectively, with 44.7% of isolates classified as DTR-PA. Multilocus sequence typing identified ST277 (18.4%), ST1076 (13.2%), and ST3012 (13.2%) as the predominant DTR-PA sequence types. The presence of bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.